Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor
- PMID: 1533234
- DOI: 10.1007/BF03348668
Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor
Abstract
In order to determine the involvement of the atrial natriuretic factor (ANF) in a model of drug-induced cardiomyopathy, the effects of a single or repeated doses of doxorubicin on plasma ANF levels were examined. Female Wistar rats were treated with doxorubicin at two different schedules: a single 10 mg/kg iv dose or multiple 3 mg/kg iv doses once a week for 3 weeks; control groups were given vehicle (isotonic saline, 0.9% NaCl) intravenously. ANF was assayed in plasma by a specific and sensitive radioimmunoassay method and cardiac function was evaluated by monitoring of ECG and hemodynamic parameters. In the doxorubicin single-dose study plasma ANF values were measured during a period of 6 hours after dosing and were found to be significantly decreased at the 180th (12.5 +/- 2.9 pg/ml) and 360th minute (19.4 +/- 1.2 pg/ml) after dosing, compared to vehicle-treated animals (35.1 +/- 5.7 and 37.9 +/- 4.1 pg/ml, 180 and 360th minute, respectively). Rats treated with multiple doses of doxorubicin showed a significant increase in plasma ANF levels at the 21st (88.3 +/- 7.7 pg/ml) and 31st day (61.0 +/- 14.3 pg/ml) of the study compared to vehicle-treated animals at the same time points (41.8 +/- 8.0 and 26.5 +/- 7.2 pg/ml, respectively). At the 42nd day plasma ANF concentration in doxorubicin-treated rats was not significantly different from vehicle-treated rats. In both studies ANF level changes occurred in the setting of acute or chronic doxorubicin-induced cardiac damage, as evidenced by alterations of hemodynamic and ECG parameters.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand.Endocrinology. 1992 Feb;130(2):755-65. doi: 10.1210/endo.130.2.1531129. Endocrinology. 1992. PMID: 1531129
-
Fetal atrial natriuretic factor and arginine vasopressin responses to hyperosmolality and hypervolemia.Pediatr Res. 1988 Sep;24(3):318-21. doi: 10.1203/00006450-198809000-00008. Pediatr Res. 1988. PMID: 2974940
-
Cardiac and noncardiac atrial natriuretic factor (ANF) biosynthesis and storage and plasma ANF in the rat model of chronic ventricular dysfunction.Endocrinology. 1989 Mar;124(3):1515-21. doi: 10.1210/endo-124-3-1515. Endocrinology. 1989. PMID: 2521823
-
The morphine effect on plasma ANF.Eur J Pharmacol. 1986 Nov 12;131(1):91-4. doi: 10.1016/0014-2999(86)90519-4. Eur J Pharmacol. 1986. PMID: 2949987
-
Atrial natriuretic factor in patients with acromegaly.Eur J Clin Pharmacol. 1990;38(5):409-13. doi: 10.1007/BF02336675. Eur J Clin Pharmacol. 1990. PMID: 2143136
Cited by
-
Soluble adenylyl cyclase in the eye.Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2579-83. doi: 10.1016/j.bbadis.2014.07.032. Epub 2014 Aug 6. Biochim Biophys Acta. 2014. PMID: 25108282 Free PMC article. Review.
-
Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.Anatol J Cardiol. 2016 Apr;16(4):234-41. doi: 10.5152/akd.2015.6185. Epub 2015 Apr 30. Anatol J Cardiol. 2016. PMID: 26642465 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical